New immunotherapies and biologics that are changing the landscape when it comes to treating patients are the most exciting development in oncology in the last year, according to Lucio Gordan, MD, of Florida Cancer Specialists.
New immunotherapies and biologics that are changing the landscape when it comes to treating patients are the most exciting development in oncology in the last year, according to Lucio Gordan, MD, of Florida Cancer Specialists.
Transcript (slightly modified)
There have been a number of developments in oncology treatment in the last year: which of those do you find the most clinically exciting?
There are several. Obviously, we cannot go in oncology without speaking about immunotherapy, the new biologics. Those drugs are potentially changing the landscape as to how we treat patients with lung cancer, melanoma, and others. So I think this is the most critical component as far as developments. We have had several new drugs approved for multiple myeloma for this year and how to sequence these drugs is a challenge.
Another important point of the clinical track that we discuss for the community of oncology physicians is to make sure that we always support clinical trial enrollment. This is the only way we can move the science forward and get our patients to do better. But, I think immunotherapy is the blockbuster for 2016.
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More